Prevention and Screening of CRC

Publication
Article
Special ReportsGastrointestinal Cancers (Issue 5)
Volume 4
Issue 2

Nadir Arber, MD, MSc, MHA, director of the Integrated Cancer Prevention Center (ICPC), Tel Aviv Sourasky Medical Center, discusses prevention and screening of colorectal cancer (CRC).

Articles in this issue
Proteomic Study in CRC of Paired Tumor Versus Nontumor Tissue May Identify New Biomarkers
Proteomic Study in CRC of Paired Tumor Versus Nontumor Tissue May Identify New Biomarkers
Managing the Elderly Patient With Unresectable HCC: Q and A With Pierre M. Gholam, MD, AGAF
Managing the Elderly Patient With Unresectable HCC: Q and A With Pierre M. Gholam, MD, AGAF
Prevention and Screening of CRC
Prevention and Screening of CRC
Survival Differences in KRAS/BRAF Mutations in mCRC
Survival Differences in KRAS/BRAF Mutations in mCRC
Surivival Benefit of Regorafenib in CORRECT and CONCUR Trials
Surivival Benefit of Regorafenib in CORRECT and CONCUR Trials
New Agents Show Potency for Patients with HCC
New Agents Show Potency for Patients with HCC
Success of Regorafenib Confirmed in Patients With mCRC
Success of Regorafenib Confirmed in Patients With mCRC
Agents Under Examination Demonstrate Success in Gastric Cancer
Agents Under Examination Demonstrate Success in Gastric Cancer
Recent Videos
Rohit Gosain, MD; Rahul Gosain, MD; and Pamela L. Kunz, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Pamela L. Kunz, MD, presenting slides
Related Content
Leronlimab Gets FDA Nod for Phase 2 Microsatellite-Stable CRC Trial

Leronlimab Gets FDA Nod for Phase 2 Microsatellite-Stable CRC Trial

Jordyn Sava
March 27th 2025
Article

A phase 2 trial will evaluate leronlimab’s safety and efficacy for the treatment of patients with microsatellite stable metastatic colorectal cancer.

Read More

Behind the FDA Approval of Fruquintinib for Previously Treated mCRC

Behind the FDA Approval of Fruquintinib for Previously Treated mCRC

Jordyn Sava;Arvind Dasari, MD, MS
November 15th 2023
Podcast

In season 4, episode 18 of Targeted Talks, Arvind Dasari, MD, MS, dives into the recent approval of fruquintinib for patients with metastatic colorectal cancer.

Listen

Survivorship Care Promotes Evidence-Based Approaches for Quality of Life and Beyond

Survivorship Care Promotes Evidence-Based Approaches for Quality of Life and Beyond

Jonah Feldman
March 21st 2025
Article

Frank J. Penedo, PhD, explains the challenges of survivorship care for patients with cancer and how he implements programs to support patients’ emotional, physical, and practical needs.

Read More

Special Episode: Insight on Targeting Rare Genomic Alterations in Colorectal Cancers

Special Episode: Insight on Targeting Rare Genomic Alterations in Colorectal Cancers

Michael J. Overman, MD;Nichole Tucker
July 15th 2021
Podcast

In season 2, episode 6 of Targeted Talks, Dr. Michael J. Overman, joins Targeted Oncology for a special discussion around rare genomic alterations in colorectal cancer

Listen

Truong Factors Age and High-Grade Toxicity Risk Into IO Selection in Melanoma

Truong Factors Age and High-Grade Toxicity Risk Into IO Selection in Melanoma

Targeted Oncology Staff
March 19th 2025
Article

During a live event, Thach-Giao Truong, MD, moderated a discussion on treating a 78-year-old patient with metastatic melanoma with immunotherapy.

Read More

Vokes Explores Biomarker Testing and Treatment Landscape for EGFR-Mutated Lung Cancer

Vokes Explores Biomarker Testing and Treatment Landscape for EGFR-Mutated Lung Cancer

Targeted Oncology Staff
March 18th 2025
Article

During a Community Case Forum event in partnership with the Texas Society of Clinical Oncology, Natalie Vokes, MD, discussed trials of targeted agents for EGFR-mutant lung cancer.

Read More